8-K: Kineta Announces Promising Clinical Trial Results for Cancer Immunotherapy KVA12123

Kineta's VISTA-101 Phase 1/2 clinical trial shows encouraging results for KVA12123, both as a monotherapy and in combination with pembrolizumab, in patients with advanced solid tumors.

Summary

• Kineta, Inc. announced an update on its VISTA-101 Phase 1/2 clinical trial at the Society for Immunotherapy in Cancer (SITC) conference.
• The trial is evaluating KVA12123, an anti-VISTA monoclonal antibody, as a monotherapy and in combination with Merck's anti-PD-1 therapy, KEYTRUDA (pembrolizumab).
• The monotherapy arm of the trial is fully enrolled with 24 patients, and the combination arm is expected to be fully enrolled by year-end.
• In the monotherapy arm, 13 of 19 patients with follow-up scans experienced stable disease, with one patient showing stable disease for 60 weeks.
• The combination therapy arm has enrolled 9 patients, with one patient showing a confirmed partial response with a 54% reduction in target lesions and a complete response in non-target lesions.
• Another patient in the combination arm showed stable disease with a 24% reduction in target lesions.
• KVA12123 has demonstrated a favorable safety profile with no dose-limiting toxicities observed in either arm of the study.

Sentiment

Score: 8

Explanation: The document presents positive clinical trial results with a favorable safety profile, indicating a promising outlook for the drug. The collaboration with TuHURA and the potential for a new treatment option for hard-to-treat cancers contribute to the positive sentiment.

Positives

• KVA12123 has shown encouraging clinical responses in both monotherapy and combination therapy arms.
• The drug has demonstrated a favorable safety profile with no dose-limiting toxicities.
• One monotherapy patient experienced stable disease for 60 weeks, indicating potential durability of the treatment.
• The combination therapy showed a confirmed partial response in one patient with a 54% reduction in target lesions and a complete response in non-target lesions.
• The combination therapy showed stable disease in one patient with a 24% reduction in target lesions.
• The drug has shown potential to address immunosuppression in the tumor microenvironment.

Negatives

• The document does not explicitly state any negative results, but it is important to note that the trial is still ongoing and further data is needed to confirm the efficacy of KVA12123.
• The number of patients in the combination therapy arm is still small (9 patients), so the results may not be fully representative.

Risks

• The clinical trial is still in Phase 1/2, and the results may not be predictive of future results in larger trials.
• The development of KVA12123 is subject to regulatory approvals and market acceptance.
• The company faces risks related to the volatility and uncertainty in the capital markets for biotechnology companies.
• There is a risk that the company's cash resources may not be sufficient to fund its operating expenses and capital requirements.
• The company is exploring strategic alternatives, which may or may not be successful.

Future Outlook

The combination arm of the VISTA-101 trial is expected to be fully enrolled by year-end. Kineta and TuHURA continue to collaborate on the ongoing Phase 1 clinical program. Kineta is exploring strategic alternatives to maximize stockholder value.

Management Comments

• Jason Henry, M.D., stated that KVA12123 has the potential to be a new alternative for patients with hard-to-treat cancers.
• Thierry Guillaudeux, Ph.D., added that KVA12123 is not only safe but exhibits potential clinical benefit for some patients as either monotherapy or combination.

Industry Context

The announcement is relevant to the immuno-oncology field, where there is a focus on developing novel therapies to overcome cancer immune resistance. The results are particularly relevant to the development of VISTA-blocking immunotherapies, which have faced challenges in the past. The collaboration with TuHURA also highlights the trend of companies partnering to advance their drug development programs.

Comparison to Industry Standards

• Competitive therapies targeting VISTA have previously shown poor monotherapy activity or induced cytokine release syndrome (CRS) in clinical trials.
• KVA12123 has demonstrated strong monotherapy tumor growth inhibition in preclinical models without evidence of CRS in clinical trial participants, which is a positive differentiation.
• The observed clinical responses, including stable disease and partial responses, are encouraging compared to the historical challenges in developing VISTA-targeting therapies.
• The combination therapy with pembrolizumab is a common approach in immuno-oncology, and the results are comparable to other combination therapies in the field.

Related Party Transactions

• Kineta entered into an exclusivity and right of first offer agreement with TuHURA Biosciences, Inc.

Stakeholder Impact

• Shareholders may view the positive clinical trial results as a positive development.
• Patients with advanced solid tumors may benefit from the potential new treatment option.
• Employees may be impacted by the company's strategic alternatives and restructuring.
• The collaboration with TuHURA may impact the company's future partnerships and collaborations.

Next Steps

• Kineta will continue to enroll patients in the combination arm of the VISTA-101 trial.
• Kineta and TuHURA will continue to collaborate on the ongoing Phase 1 clinical program.
• Kineta will continue to explore strategic alternatives to maximize stockholder value.

Key Dates

Keywords

KVA12123, immunotherapy, VISTA, cancer, clinical trial, monoclonal antibody, pembrolizumab, KEYTRUDA, oncology, tumor, SITC